Q-omics provides the consensus-scored TM4SF19 profile across patient tissues and cancer cell-line models. TM4SF19 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TM4SF19 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, TM4SF19 RNA expression shows 12,977 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KIRC, HNSC, and ESCA as cancer lineages where TM4SF19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TM4SF19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TM4SF19 survival associations across molecular data types. TM4SF19 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TM4SF19 RNA expression–survival associations across cancer types. High TM4SF19 expression shows unfavorable associations in KIRC, ACC, BLCA, UVM, MESO and LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TM4SF19 RNA expression.
This table summarizes TM4SF19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for TM4SF19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TM4SF19 shows higher tumor expression in HNSC, COAD, BLCA, KIRC, KIRP and THCA. The HNSC box plot shows higher TM4SF19 RNA expression in tumor versus normal tissue (log2 FC = +3.449, t-test p < 0.001).
This table shows molecular features associated with TM4SF19 in patient tissues and cancer cell lines. In patient samples, TM4SF19 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, TM4SF19 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BREAST.
